Health 2.0 Asia 2016 International Summit on Smarter Healthcare & Great Health Industry
Health 2.0 Asia 2016 International Summit on Smarter Healthcare & Great Health Industry will be held in Nanjing, China for 2 full days (November 9-10) of content exploring smarter healthcare & great health industry. The conference will bring together industry leaders, stakeholders and innovators from home and abroad in an effort to support the rapidly-expanding healthcare market. Our event is the platform to see cutting-edge innovation that’s currently transforming health and health care, plus the best minds sharing their insights on compelling panel discussions, keynotes, breakout sessions, and workshops.
● High-level Presentations Covering Unique and Hot Topics in the Healthcare Industry
● Project Matchmaking Fair on Bio-medicine, Health Industry Professionals
● Opportunity to Join High-end Experts’ Talk Proposed by the Nobel Prize Laureate
● Promotion Activities to be Provided for Smart Healthcare and the Latest Technology in the Medical and Health Industry
● Paralleled with Popular Science Fair
Professor Daniel Shechtman, Nobel Prize Laureates in Chemistry (2011)
To be updated soon
Dr. Pramod K. Gaur, Adjunct Professor, Pace University, USA
Dr. Hui Che, Managing Director, Accenture Healthcare Greater China
Dr. Jilan Liu, JCI Lead Consultant, HIMSS Vice President and Greater China Executive Director of HIMSS, China
Dr. Barry P Chaiken, President, DocsNetwork Ltd.; Adjunct Professor, Boston University, USA
Dr. Shou Bai Chao, Senior Vice President, AstraZeneca BioVentures, USA
Dr. Shahid Ali, GP, Director and Professor of Digital Health, University of Salford, UK
Dr. Yadong Li, General Manager of APAC, Intel Health and Life Sciences , Intel Corporation
Mr. Karthik Ranjan, Director, Healthcare Technology, ARM, USA
Mr. Leonard Shapiro, Founder, mHealth Israel, Israel
Dr. Nina M Antoniotti, Executive Director, TeleHealth and Clinical Outreach, Southern Illinois University School of Medicine and Health Care, USA
Dr. Jigeng Bai, President, Shanxi Children's Hospital, Shanxi Province Maternity Hospital, China
Dr. Chi-Meng TZENG, Professor, Xiamen University, China
Dr. Charlie Easmon,Medical Director, Your Excellent Health Service, UK
Dr. Mashiur Rahman,Project Manager, BioMed.Asia, Singapore
Dr. Milton Chen,CEO, Vsee, USA
Dr. Ivana Balter - Haluskova, Administrative Board Member, French Society of Immunology, France
Dr. Jian Li, Intel's Precision Medicine Business Leader in China & Greater Asia
Mr. Anthony Polychronakis, European Liaison Officer, Social Development Department, City of Rotterdam, The Netherlands
Mr. Christian Schulze, Global IMCM Strategy and Partnerships Manager, Bayer Pharma AG, Germany
Dr. Christian D. Orejudos, Chief Operating Officer, Yosemite Clinic, China
Mr. Alberto de Rosa Torner, CEO, Ribera Salud Group, Spain
Dr. Alex Kuo,Associate Professor, School of Health Information Science, University of Victoria, Canada
Dr. Tiliang Deng, Founder & Chief Scientist, Dream Bioscience, USA
Dr. Lihu Yang, Formerly Director, Medicinal Chemistry, Merck & Co. USA
Dr. Nazmul Hossain, Assistant Professor, Department of Marketing, University of Dhaka, Bangladesh
Dr. Josh Luke, University of Southern California, Sol Price School of Public Policy, Hospital CEO, Best Selling Health Care Author of 2015, Strategic Advisor to Renzi Corporation on its Healthy City Project in Chongqing, USA
Ms. Tory Cenaj, Founder and Publisher, Telehealth and Medicine Today, USA
Dr. Lei Xiong, Founder, 3D Medicines, Shanghai, China
Dr. Xueping Quan, Vice President & CTO, Vishuo Biomedical Pte Ltd., China
Dr. Irene Caesar, CEO, Matrix Ltd., Russia; President, Wave Genome, USA
Dr. Alain L. Fymat, Professor, International Institute of Medicine and Science, USA
Mr. George Li, CEO, Wuhan Optics Valley Bridgebio International Corporation, China
Dr. Yair Alegranti, CEO, TRS (Top Research Services) Ltd., Israel
Dr. Mingde Xia, Senior Director, Johnson & Johnson Innovation Center AP
Dr. Abdennour El Rhalibi, Professor, School of Computing and Mathematical Sciences, Liverpool John Moores University, UK
Pramod Gaur is the Chair of mHealth SIG at American Telemedicine Association, Adjunct Professor at Pace University and Clinical Assistant Professor at Stony Brook University. Dr. Gaur was responsible for the enterprise level coordination of TeleHealth at UnitedHealth Group from 2010 to 2014. Prior to that, he was the founding President and CEO of two TeleHealth companies (Viterion and Health anywhere). Dr. Gaur’s activities a digital health industry advocate include demonstrations to the US Presidential Advisor, US Congress, The White House Conference on Aging and International Delegates at the United Nations. Dr. Gaur was inducted to the 2013 ATA Class of Fellows. Dr. Gaur received his doctoral degree from the University of Kansas and received his postdoctoral training at the University of Wisconsin and the University of Maryland, School of Medicine.
Dr. Hui Che, the managing director of Accenture Healthcare Greater China, a member of "Chinese Hospital Construction Guide" editorial committee, council member of the “Journal of Director of Chinese Hospital”, standard editor of Chinese green hospital construction, an expert of Shanghai Shen-Kang Hospital Developing Center, a former standard committee editor of nursing homes of Irish Ministry of Health and Care Institutions for Disabled Persons, attending the Conference for Hospital Directors many times as specially invited guests, she has attended the 2015 Annual Meeting for Hospital Directors recently and gave a presentation on " Resources Integration - To Build Open Win-Win New Medical Formats" in the Keynote Forum. She has more than 20 years experiences in the healthcare industry and business consulting, also good at hospital operation management/hospital JCI evaluation/doctor-patient relationship management/business process optimization/pension agency management consulting. She has been in offices of Vice President of hospital and COO, etc.. In charge of hospital operation management affairs such as human resources, clinical departments, International Health Department, JCI accreditation, informationalization construction and so on. She has also participated in the whole process of planning and construction of new hospitals and nursing homes in China, Saudi Arabia and the European countries. She has rich clinical and management experiences, and leads the team to complete strategy planning, organization, control and management system of a large insurance company to enter the Chinese market, also multiple medical center planning and construction. She has served as the Professor, President, Clinical Medical President, Orthopaedic Dean, Director of Bone and Joint Research Center in Ninth People's Hospital Affiliated to Shanghai Second Medical University, also as Director of the Shanghai Joint Surgery Clinical Medicine Center, Director of the Digital Medical Engineering Research Center Ministry of Education, Director of Clinical Transformation of 3D Printing Technology Research and Development Center in the Ninth Hospital, President of World Chinese Orthopaedic Association, President of the Asia Pacific Artificial Joint Association, Director of the Institute of International Internal Fixation and Chair of Chinese branch, Vice-President of the International Society for Multidisciplinary Biological Material, Vice Dean of Chinese Orthopaedic Society. Successively won the First Inventor of Shanghai, 97 Hong Kong outstanding visiting scholars, Honorable Awards of Shanghai Medical Science, Awards of Liang He & Li He Science and Technology Funds, Credit of Shanghai Science and Technology, Awards of Jieping Wu Medicine, won the honorary of French National Medical & Technology Academy foreign communication academician.
Dr. Shou-Bai Chao is former president of Chinese Biopharmaceutical Association. He is currently Senior Vice President leading AstraZeneca's BioVentures business unit to develop Biosimilars and BioBetters for global markets with leading biotech companies in China and other Asian countries. Prior to the current responsibility, Dr. Chao was Senior Vice President of Technical Operations and Manufacturing at Medimmune, a biological division of AstraZeneca. He was responsible for global operations of commercial and later stage clinical products (vaccines and antibodies) manufacturing and technical operations. Prior to joining Medimmune, Dr. Chao served as assistant vice president, Technical Operations and Product Supply at Wyeth Biotech. He was responsible for global technical operations for the flagship vaccine, Prevnar(R) and other Biopharmaceuticals. He brings comprehensive perspective with more than 20 years’ experience at Medimmune, Wyeth, Sanofi-Pasteur and Genentech in global vaccine and biopharmaceutical process and product development, manufacturing operations and quality assurance. Dr. Chao earned his doctorate and completed his postdoctoral fellowship in Biochemical Engineering from University of Waterloo, Canada.
Dr. Mashiur has 15 years of IT, BioMed and eHealth experiences. He manages regional and global roles, managing offshore and in-house software development teams in India, Vietnam, Singapore, Malaysia, Indonesia and Japan. He is leading the eHealth platform development team that provide an end to end connected solution for remote patient monitoring. He hold Bachelor and Masters in Electrical Engineering and PhD in Physics from Japan.
Mr. Dennis Lottero is the founder and managing director of Metamorphic Global Solutions, which is bridging the gap between Internet of Things (IoT) technologies and global medicine. Metamorphic Global Solutions works with a variety of clients in the healthcare market to provide strategic advice / guidance in the development and deployment of medical solutions that take advantage of mobile internet technologies. Clients include medical device manufacturers looking to remotely monitor and manage medical devices installed globally, pharmaceutical companies looking to automate clinical trials, international NGO/care organizations seeking to understand how to take advantage of global wireless technologies to be more efficient and effective in the delivery of care to underdeveloped countries. Metamorphic’s goal is to make our clients most effective in solving existing business problems, opening new markets, or creating new products through the practical use of internet and cellular technologies. Mr. Lottero’s speech title in our conference is “Remote Monitoring and Management of Globally Deployed Medical Devices - the Benefits and Challenges”.
To be updated soon
Dr. Charlie Easmon, President of The International Association of Physicians for the Overseas Services (IAPOS) www.iapos.co.uk; Co-founder of Global Health Action Strategies and Solutions (www.ghass.co.uk); Honorary Lecture at UCL Performing Arts Medicine; Lecturer Diploma Course in Occupational Medicine at the Royal Society for Public Health (ww.rsph.org.uk); Founder of www.blackaction4health.com. Dr Easmon trained at St George's. London. He did his elective in Ghana (his country of birth) and has since worked with, among others, Merlin, Raleigh International and Save the Children in Rwanda, and ECHO in Armenia, Georgia and Azerbaijan. With the Foreign Office he has visited Egypt, Israel, Tunisia, Japan, Korea, Taiwan and the Philippines. In 2009 he re-visited Rwanda and has since done medicals or given talks in the Congo, Botswana and Mozambique. His expertise in to travel medicine and public health was through medical evacuations, working abroad and stints at the Hospital for Tropical Disease's travel clinic. He enjoyed several years on the board of the British Travel Health Association and is one of the few UK medical practitioners to have obtained the International Certificate in Travel Health from the International Society of Travel Health. in 2008 Charlie became a member of the new Faculty of Travel Medicine - MFTM RCPS (Glasg). Charlie’s interest in mental health in the workplace came late through his occupational health work in which he saw the consequences of poor work environments, late referral, lack of mental health support resources or poor management. He has built his own private medical business through various (at times stressful) ups and downs over the last 10 years and counts 12% of the FT100 amongst his clients. The current business is called Your Excellent Health Service www.yourexcellenthealth.co.uk and is based at 1 Harley Street.
Dr. Alex Kuo holds a PhD from the Department of Computer Science, University of Nottingham, UK. He is a full time associate professor at the School of Health Information Science, University of Victoria, BC, Canada. He was a visiting scholar at the Electronic Commerce Resource Centre (ECRC), Georgia Tech. (1999-2000), and the Center for Expanded Data Annotation and Retrieval (CEDAR), School of Medicine, Stanford University (2015-2016). Now, he is the chair of the IEEE Big Data Education Track and the study group leader of Metadata Standard for Big Data Management at the IEEE Big Data Initiative (BDI). With over 20 years of programming and data analysis practical as well as research experience, he has over 140 peer-reviewed publications. His research interests include health Big Data analytics, health data interoperability, health database & data warehousing, data mining application in healthcare, e-health and clinical decision support system.
Dr. Qun (Max) Dang, Asia Head–External Innovation, Endo & CV Research at Eli Lilly and Company.
Max joined Gensia pharmaceuticals (later became Metabasis) in 1992 and worked until 2009 with his last position as director of medicinal chemistry. During his time at Metabasis, Max managed multiple drug discovery projects primarily in metabolic disease areas such as diabetes and dyslipidemia (such as FBPase inhibitors, glucagon antagonists, glucokinase activators, and AMPK activators). Since joining Merck in 2009, Max managed several integrated drug discovery projects carried out at various CROs in the areas of diabetes, infectious disease and endocrine related diseases. His teams delivered multiple PCCs for HIV, HCV, diabetes, and Alzheimer’s disease. His research interests include medicinal chemistry via rational drug design, heterocyclic chemistry, prodrugs, and nucleoside chemistry. Dr. Dang has authored or co-authored 87 publications in peer-reviewed journals, 2 book chapters, and 60 granted patents and applications.
Mr. Levi Shapiro is the Founder of mHealth Israel, a non-profit supporting Israel’s digital health startup community, with more than 2800 members and the largest digital health conference in the Middle East. During a 20 year career, including 7 in Tokyo and Beijing, Levi launchednew business units (IBM), new products (Toyota) and several startups. He is an investor and Board Member in several Israeli digital health startups. He also leads corporate development for HeraMED. Mr. Shapiro is an Adjunct Professor at IDC Herzliya, teaching Entrepreneurial Marketing and the Healthcare Business Module in the Adelson School of Entrepreneurship. He has degrees from Tulane (BA), Cornell (Asian Studies) and MIT (MBA).
Dr. Antoniotti is the President/CEO of AthenaWerx TeleHealthTransformational Consulting, and is also SIU HC and School of Medicine’s Executive Director of TeleHealth and Clinicial Outreach, Springfield, Illinois. Dr. Antoniotti has over 20 years-experience in virtual care strategies and started working in telemedicine after 20 years-experience in hospital health care. Dr. Antoniotti has received attention for her pioneering efforts in the development of TeleHealth, being one of the early professional success stories in the late1990’s starting Marshfield Clinic’s TeleHealth program. She quickly became one of the nation’s leaders in business planning, provider and patient adoption, clinical operations, technology innovation, and integration of TeleHealth into clinical systems of care.
Dr. Antoniotti is past Chair of the American Telemedicine Association Standards and Guidelines Committee, past-chair of the ATA Policy Committee and current member, a past Board Member of the American Telemedicine Association, and is past Vice-President of the Board of the Center for Telemedicine Law, Washington, DC. In 2007, Dr. Antoniotti received the American Telemedicine Association’s President’s Award for Individual Achievement in the advancement of Telemedicine world-wide. She has been instrumental in helping many programs initiate, and become sustainable in their telemedicine applications. In 2009, Dr. Antoniottiwas one of 10 people in the world inducted into the American Telemedicine Association’s College of Fellows for her contributions to ATA and the world of telemedicine. Dr. Antoniotti is also recognized for her international efforts to deploy TeleHealth initiatives and has worked in China to set up TeleHealth services between the United States and Hangzhou, Zheijing, China (2007-2009), and was invited to assist and worked with Iran’s Minister of Health and the University of Tehran in understanding how to deploy a national TeleHealth strategy for the people of Iran in 2010.
To be updated soon
Dr. Jilan Liu, Principal & JCI Consulting Director, Greater China; Vice President & Executive Director, Greater China at HIMSS. Dr. Jilan Liu has extensive healthcare experience, connections and exposure in the United States, China, and more than 20 other countries around the world. Her experience is not only broad geographically, but also very diverse across healthcare sectors and dimensions: Public/private hospitals and academic medical centers, large physician group practices, health insurance including HMOs, IT companies and associations, public health, accreditation and health policy research, etc. Dr. Liu has devoted her effort in reshaping healthcare delivery through standards/accreditation, sharing best practice in patient/staff experience, organizational performances and transforming healthcare care through IT technology. As the Principal Consultant for JCI around the world and Lead Consultant for its China Practice, Dr. Liu has provided consultation services to hundreds of hospitals in more than 20 countries in the past ten years, including more than 50 hospitals within China. She and her teams have guided client hospitals in transforming their clinical and managerial operations toward better patient safety, higher quality, more respect with personalized care/attention, and greater operational excellence. As Vice President and Executive Director for HIMSS Greater China, Dr. Liu realized a significant start up and breakthrough to help transforming healthcare through IT technology. She developed partnerships and collaborations with key industry players and attracted major hospitals to embark on HIMSS EMRAM Stage 6 and 7 journeys.
Barry P. Chaiken, MD, MPH, as over 30 years experience in health information technology, patient safety, and clinical transformation. He is currently President of DocsNetwork Ltd. where he offers clients his expertise in business development, clinical transformation, strategy formulation, and informatics. Chaiken served as a Board member, Board Liaison to HIMSS Europe, and Board Chair, and continues his involvement as a Fellow of HIMSS. He currently writes a column on technology and quality for the journal Patient Safety and Quality Health Care and contributes to the online publication Health Data Management. Chaiken is board certified in General Preventive Medicine and Public Health. Chaiken received his medical degree from Downstate Medical Center and his MPH degree from the Harvard School of Public Health. He acquired his specialty training from the Centers for Disease Control as an Epidemic Intelligence Service officer and from the NJ Department of Health as a preventive medicine resident.
Sina Iluyemi consults and advises on digital health innovation, policy and strategy development. He offers unique knowledge about digital health innovation, implementation and entrepreneurship by combining knowledge from diverse multidisciplinary subjects and areas. He is the founder and a consultant at the UK-based Healthtronics consultancy and advisory where he is advising UK start-ups and companies. He is an invited speaker at conferences and he co-organises a digital health innovation and entrepreneurship event in London, UK. Prior to this, he co-founded MoDiSe, a mobile medical diagnostic company. Dr Iluyemi has advised countries on the development and implementation of their national eHealth policies and strategies with the Commonwealth Secretariat. He is a mentor on Mass Challenge Accelerator Programme, a non-Exec of Comuzi, a digital design and innovation factory, and an Advisory Board Member of the EU WELCOME digital health wearable project, and since 2012, a GSMA Global Mobile Award Judge. Dr Iluyemi trained as a dental surgeon and received a PhD in Health Informatics in the UK and a Diploma from the Royal College of Surgeons, England.
Dr. Yongji Fu, R&D Director at Hill-Rom, USA. Dr. Fu is a global technology and innovation leader with over 15 years' experience in medical device industry. He has held multiple R&D leadership roles at top global companies in healthcare domain, is a globalist and have been trained in both US and China, and served companies originated from North America, Europe and Asia. He has earned credibility in life science including organizer for a number of international conference, numerous
invited speakers for universities and conferences, grant reviewers and journal reviewers. In Hill-Rom, he Leads corporate R&D in the scope of wearable sensing, information driven patient care, consumable device and advanced network technologies for NPD (New Product Development) pipeline.
Dr. Mashiur Rahman is the R&D Manager in ConnectedHealth Pte Ltd. in Singapore. He is an electrical engineer with 12 years experience in developing biosensors, bioinstrumentation, e-health and digital health solution in USA, Japan and Singapore. Mashiur did his undergraduate and masters at Toyohashi University of Technology (Japan) and pursued his doctoral work on biosensor with Professor Tsuneo Urisu at the The Graduate University for Advanced Studies (Japan). Then postdoctoral work at Marshall University (USA) and National University of Singapore. At ConnectedHealth he is leading the R&D team to develop core products and solutions.
Mr. David Groberman is the CEO / Co-Founder of HeraMED in Israel. Also R&D of multi-disciplinary medical and hi-tech devices for over 15 years. He has Extensive knowledge and capabilities in the medical devices industry, leading some of the most challenging projects in this field. Ranging from implants to invasive mechanical, electro-mechanical and opto-mechanical instruments. Surgical apparatuses and applicators, monitoring, diagnosis and scanning equipment. B.Sc. cum laude - in Bio-mechanical engineering, TAU.
Prof Shahid Ali is a clinical leader with strategic vision and a passion to improve services and achieve better health outcomes for patients. He works as a general practitioner specialist, and has held senior NHS management roles at local and regional levels. He is co-founder and a Director of Dynamic Health Systems. Until recently he has been working closely with NHS England as a National Clinical Leader. Currently he is working on several work streams including empowering and enabling patient centred care using technology, integration of services across pathways and intelligence for commissioning. He is Professor of Digital Health in the University of Salford.
Dr. Ivana Balter – Haluskova, MD specialised in infectious diseases and vaccinology (MBA) with years of experience in pharmaceutical research and development, focused on India/Asia countries during last years.
Dr. Milton Chen is the founder and CEO of VSee. VSee is a California telehealth company. VSee built the video telemedicine system for the NASA International Space Station, as well as MDlive, Walgreens, InternationalSOS, Davita and the three largest healthcare systems in the USA. VSee is based on the VSee telehealth operating system – a set of building blocks making telehealth implementation easy and flexible. Milton did his PhD at Stanford University on the design of video collaboration. He was the co-author of XMPP video standard (XMPP is used by Google Talk and Facebook Chat). He has deployed vsee for Hillary Clinton, Angelina Jolie, the rock band Linkin Park, and UN Secretary General Ban Ki Moon. Milton has also traveled to Iraq twice, drove across Syria and participated in numerous medical missions in Africa and Southeast Asia.
Dr. Jian Li, A healthcare leader, innovator and strategist, with proven track records in clinical & home-use medical devices, In-vitro diagnostics, regenerative medicine, genomics medicine and Health-IT solutions. Over 12 years' multi-functional working experience in MNC healthcare giants (PHILIPS/MEDTRONIC/SIEMENS/ INTEL), mainly taking global/emerging markets strategy, marketing, R&D and innovation management role. Currently, Jian is Intel's Precision Medicine business leader in China & Greater Asia and leading an architecture/engineering/user experience/business team on driving new solutions development, ecosystem maturity and revenue growth.
Anthony Polychronakis, MA is currently the European Liaison Officer at the Social Development Department of the city of Rotterdam. He is the advisor on matters of international relations and European funding. He studied Public Administration and European Studies at the Erasmus University of Rotterdam, Leiden University, and Panepistimio Kritis of Crete, Rethymnon. As a senior policy adviser he was responsible for the Rotterdam approach to domestic violence and elder abuse. He is also the co-founder and a board member of the European Family Justice Center Alliance (EFJCA). Polychronakis' career also includes a wide assortment of political activities. He was a politician and an elected member of the City Council of Alphen aan den Rijn, the Netherlands.
Christian Schulze has more than 15 years of digital & e-business experience, consulting in travel, banking, energy, entertainment and marketing industries to embrace new digital capabilities. Christian holds Bachelors of Science in Digital Media and Computer Science and a Master in E-Business. Christian has joined Bayer’s pharma division in 2008 and held various global positions with increasing responsibilities to digitalize commercial operations. Since the beginning of 2016 Christian is responsible to drive global strategy and partnerships in the newly established Center of Excellence for Integrated Multichannel Marketing.
Dr. Christian Orejudos, Executive Vice-President and Chief Operating Officer, Shanghai Redleaf International Women's Hospital, China. To put his Doctoral, MBA and Healthcare leadership skills into practice in any situation that is handed to him and to perform in a manner that encompasses my professional experience and knowledge. Specialties: Excellent management and process improvement skills, strong customer service, communication and teaching skills; knowledgeable in medical terminology & process improvement; proficient in MS Office Applications. Studied and implemented Customer Service Initiative programs for Service Excellence under Quint Studer. Experienced in Joint Commission (JCAHO & JCI) Accreditation (Preparation and Audit).
Alberto de Rosa is the CEO of Ribera Salud Group. He has had an extensive career in the health sector, with over 26 years of experience managing different hospitals. Alberto is a graduate in Economics and Business Studies from the University of Valencia, MBA from ESADE and Master in Health Care Management. Ribera Salud is the leading healthcare management business group in the PPP sector in Spain. The company has played a pioneering role in the development of PPPs, such as the integrated healthcare system based on a capitated payment. Alberto has presented the Ribera Salud Management Model in many international forums and have shared knowledge with various governments, universities, multilateral bodies, managers, and professionals interested in learning and studying this pioneering system.
To be updated soon
Dr. Deng is founder and chief scientist of Dream Biosciences in San Diego, CA. He was founder and CEO for 10 years of AD&D Biotech in San Diego, CA. Earlier, he was tenure-track assistant professor in biochemistry at University of Florida. He did his postdoc with Michael Karin (US academy member with 69 papers in Cell, Science and Nature) at UCSD. He obtained his PhD from Ohio State and his MBA from Cornell. He has published many papers in top tier journals, including 6 papers in Cell and Nature (2 are first author papers). He has 4 US patents, which have been licensed to Celgene (market cap at $100B). He was one of the 59 CUSBEA students selected from entire China in 1982.
Dr. Yang most recently led the Merck chemistry efforts on tuberculosis, working with the TBDA (tuberculosis drug accelerator, sponsored by the Bill and Melinda Gates Foundation). He has over 26 years of experience in drug discovery at Merck, spanning in the field of immunology, oncology, infectious diseases, cardiovascular, obesity and diabetes. Dr. Yang received his PhD from Rice University in organic chemistry. He served as the president of the Sino-American Pharmaceutical Professionals Association (SAPA) in 2000. He has been an adjunct professor of Peking University’s Master Degree Program of International Pharmaceutical Engineering Management, 2007-2016. Dr. Yang has authored and co-authored over 60 publications and over 60 patents. He has been an editor for two medicinal chemistry journals.
Md. Nazmul Hossain is an Assistant Professor of Marketing at University of Dhaka, Bangladesh. He is the project advisor to Portable Health Clinic (PHC), an eHealth initiative aiming to provide affordable quality healthcare services to low income, low educated rural communities in developing countries. His responsibilities include ensuring business sustainability of PHC through analyzing healthcare buying behavior of rural consumers. Mr. Hossain is also a Social Business activist having a numbers of published articles on contemporary global social business issues. Currently he is also serving as an academic advisor to Yunus Centre (where Professor Muhammad Yunus, the 2006 Nobel Peace Laureate is the chairman) to promote social business education in the universities around the world. He has delivered several seminar lectures on ‘Social Business and Healthcare’ in Bangladesh, Austria, Singapore, Germany, Poland, Malaysia, China, Japan, Mexico and USA.
Dr. Josh Luke is an international motivational speaker and America’s leading healthcare futurist. He is an experienced hospital CEO (in Los Angeles, Anaheim and Las Vegas), health system Vice President, nursing home administrator and assisted living Executive Director. He is an expert on the Affordable Care Act and how it will shape the continuum of care and leads organizations on obtaining revenue growth in a post-Obama Care model. In 2015, he began providing strategic counsel to the Renzi Corporation on its Healthy City Project in Chongqing, China. He currently serves as Chief Strategy Officer for Nelson Hardiman Healthcare Law. Dr. Luke was selected to author the book Readmission Prevention: Solutions Across the Provider Continuum published by the American College of Healthcare Executives, the best-selling book from Health Administration Press in 2015. In 2016, Xlibris publishing released Luke’s first book written for the mainstream public, Ex-Acute: A former hospital CEO tells all on what’s wrong with American healthcare, What every American needs to know. His broad range of experience with several of the leading companies in healthcare, includes serving as CEO of HealthSouth Las Vegas (acute rehab hospital), Administrator in the Skilled Nursing Division of Kindred, and as VP Post Acute Services for Torrance Memorial Health System overseeing home health and hospice services. He founded the National Readmission Prevention Collaborative online at www.nationalreadmissionprevention.com and serves as adjunct faculty at the University of Southern California, Sol Price School of Public Policy. He is a Lean Six Sigma Black Belt and board appointments include California Hospital Association Post Acute Board of Directors, Alzheimer’s Orange County, Hospital Association of Southern California, Healthcare Executives of Southern California, CSULB Healthcare Administration Advisory Board and Hospice Care of California.
Tory Cenaj is Founder and Publisher of the innovative new online journal Telehealth and Medicine TodayTM. She has extensive experience in healthcare publishing and communications, managing medical journals, publication planning, continuing medical education, and digital health portfolios. Ms. Cenaj has held positions in biopharm, advertising, medical communications and research facets of the healthcare industry at Bristol Myers Squibb, Accenture, and Quintiles Innovex. She founded the medical education company PharmEd Communications; and led marketing, digital and international licensing in Europe, Asia, Middle East and Latin America at Advanstar Healthcare. Ms. Cenaj received her BA from Smith College in Northampton, Massachusetts.
Dr. Xiong got his phD in Chinese academy of Sciences, where he was trained as a cancer cell biologist focusing on using genomic tool to explore mechanisms of target therapy and chemotherapy. He found IGF-1R signaling could regulate apoptosis by affecting p53-Mdm2 feedback loop. This finding indicates that targeting RTK signaling does not always attenuate cell survival and could inhibit chemotherapy-induced apoptosis. During his postdoctoral studies, he focused on constructing an animal model to study how signaling among different organs affect cell autophagy. He also set up an in vivo model to screen apoptosis-stimulating drugs by using a caspase-cleavage system. By the end of 2010, Dr. Xiong came back to China and founded 3DMedicines, which aims to develop next generation diagnostic tools and precised anti-cancer drugs based on gene mutation. Currently, 3DMed has more than 350 employee and has more than 6 offices in China and 2 CLIA labs. Every year, 3DMed performed near 10,000 cancer smaples by using NGS tools. Notably, 3DMed also developed drugs including PD-L1 antibody and small molecualr TKIs.
Xuepin Quan is the Vice President & Chief Technology Officer of Vishuo, leading the R&D teams of Vishuo and is responsible for the strategic design, development, implementation, and delivery of Vishuo’s products. Dr Quan was a Bioinformatics Consultant to provide solutions on NGS data analysis and annotation, genomics data integration, and semantic integration of diverse information sources for multiple international biotech/pharmaceutical companies and top universities. She received her doctoral degree on bioinformatics from the University of Edinburgh, and postdoctoral training at the Centre of Intelligence Systems and their Applications of the University of Edinburgh, the School of Medicine of Kings College London, and Imperial College London.
To be updated soon
Alain L. Fymat, PhD, PhD is a medical scientist and an educator. He was educated at the University of Paris-Sorbonne and the University of California at Los Angeles. He is the current President/CEO and Professor at the International Institute of Medicine and Science with a previous appointment as Executive Vice President, Chief Operating Officer and Professor at the Weil Institute of Critical Care Medicine, both Institutes located in Rancho Mirage, California, USA. He was formerly Professor of Radiology, Radiological Sciences, Radiation Medicine (Oncology), and Physics at several U.S. and European Universities. Previously, he was Deputy Director (Western Region) of the U.S. Department of Veterans Affairs, Veterans Health Administration (Office of Research Oversight), and Director of the Magnetic Resonance Imaging Center and for a time Acting Chair of Radiology at its Loma Linda, California Medical Center. Dr. Fymat’s current research interests lie at the interface between science and medicine (particularly molecular medicine, personalized medicine, nanomedicine, and human genetics/epigenetics/ecogenetics). He is Honorable Editor of the “Journal of Cancer Prevention and Current Research” and the “Journal of Nanomedicine Research” and Editor of the Journal of Nanobiotechnology.
Irene Caesar, Ph.D., is a Co-founder and CEO of Matrix Ltd., Russia, company creating global subscription platforms for bioelectronic drugs (founded 2016); Founder and President of Wave Genome, company producing bioelectronic devices and software for the distribution of bioelectronic drugs for rejuvenation only (founded 2010); Co-founder of “Matrix City” Consortium with the Institute for National Security in Moscow for building self-sufficient human settlements based upon the remote management of biosystems, climate and geophysical processes for the first time in the history of humankind (founded 2012), presented in the Honorary Lecture at the Harriman Institute of the Columbia University in September 2012; Co-founder of the Quantum Biointernet for the remote rejuvenation via distant laser signal, commercially offered for the first time in the history of humankind by Irene Caesar’s company Wave Genome in May 2013; Colonel of Irkutsk Cossack Military, awarded the Medal of Faith and Service to Russia (2014). Dr. Caesar received her doctoral degree from the Graduate Center of the City University in New York.
To be updated soon
To be updated soon
Abdennour El Rhalibi is Professor of Entertainment Computing and Head of Strategic Projects at Liverpool John Moores University. He is Head of Computer Games Research Lab at the Protect Research Centre. He has over 23 years’ experience in research and teaching in Computer Science. His research involves Game Technologies and Applied Artificial intelligence. He has been leading for six years several projects in Entertainment Computing funded by the BBC, involving cross-platform development tools for games, 3D Web-Based Game Middleware Development, Multiplayer Online Games, Peer-to-Peer, 3D Character Animation and Health Care Security using Visualization Techniques. Abdennour has published over 170 publications in these areas. He has served as chair and IPC member in over 100 conferences on Computer Entertainment, AI and VR. Abdennour is member of many International Research Committees in AI and Entertainment Computing, including IEEE MMTC IG: 3D Rendering, Processing and Communications.
Dr. Mingde Xia is currently a Senior Director of Johnson & Johnson Innovation Center AP, and a vice Chair of Asian Society for Innovation & Achievement (A.S.I.A.) in USA and Canada. He focuses on business development in mainland China, Hong Kong, Taiwan, and Korea etc. with universities, institutes, investors and innovative companies for J & J worldwide pharmaceuticals, medical device / diagnostic products and OTC / consumer business, through investment, incubation, co-development, license and other collaboration vehicles. He has been working with Johnson & Johnson for 16 years after career track at China Pharmaceutical University and Yale University, and has successfully led / executed over 50 projects external collaboration for Johnson & Johnson three sectors. He is a guest / adjunct professor at the Chinese Academy of Sciences, a major inventor / author of over 60 patents / publications, a reviewer for a number of top quality international scientific journals, and an invited speaker for many international pharmaceutical conferences / forums. He received awards from American Chemical Society, Johnson & Johnson and different universities. He has actively involved in Sino-American Pharmaceutical Professionals Association (SAPA President 2009, Board of Directors 2008-2016) and organized many international conferences in USA and Asia.
To be updated soon
Block 1: Main Conference
Part 1: Opening Ceremony
Part 2: Keynote Forum: Global e-Health Frontier
Part 3: Nobel laureate’s Lectures
Part 4: Symposium: The Innovation and Development of Biopharmaceutical in the Era of Health 2.0
Block 3: Business, Social and Cultural Activities
Activity 1: Welcome Banquet and Art Performance
Activity 2: Talent, Project and Investment Matchmaking
Activity 3: Meet with Your Potential Partners
Activity 4: Romantic Cultural Tours in Nanjing
Nanjing Jiangbei New Area Administrative Committee
Health 2.0 LLC
Wellness IT Association
Nanjing High-Tech Zone Administrative Committee
BIT Group Global Ltd.
Nanjing Biotech and Pharmaceutical Valley
Nanjing International Healthcare Area
Ms. Rikky Gao
East Wing, 11F, Dalian Ascendas IT Park
No. 1 Hui Xian Yuan, Dalian Hi-tech Industrial Zone
LN 116025, P. R. China
Tel: 0086-411-84799609 Ext. 804